FeesSafety
Pluang+

Elysium launches as first Arbitrum layer-2 on HyperEVM, boosting DeFi capacity and performance.

Protocol Fundamentals
10 Nov 2026, 14:44 WIB
Tokenpost
View Source
Bullish
Elysium launches as first Arbitrum layer-2 on HyperEVM, boosting DeFi capacity and performance.

Elysium, built by Kinetiq, is the first dedicated Arbitrum layer-2 solution to settle on HyperEVM, designed to enhance execution capacity and performance for applications and traders within Hyperliquid's DeFi and perpetuals ecosystem. This development aims to provide greater scalability and improved transaction efficiency for users in the growing decentralized finance space. By integrating with HyperEVM, Elysium supports the expansion of Hyperliquid's programmable economy, potentially attracting more users and developers to the platform. This move highlights ongoing innovation in blockchain infrastructure to meet increasing demand in DeFi markets.

Elysium's recent development is context for readers following major cryptocurrencies. As of Nov 10, 2026 19:44 WIB, 30 of 50 major cryptocurrencies on Pluang rose, 19 fell. EOS rose 8.13% to Rp12.649 with a typical hold time of 87 days. AAVE fell 6.09% to Rp2.254.622 with 88% buy orders. SAND rose 3.74% to Rp784 with 80% buy orders.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
1 hour ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
1 hour ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
1 hour ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
1 hour ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App